A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

Most melanomas harbor oncogenic BRAF(V600) mutations, which constitutively activate the MAP kinase (MAPK) pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF(V600)-mutant melanoma, it remains incompletely understood why 10-20% of patients fail to respond. Here, we show that RAF i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Konieczkowski, David J., Johannessen, Cory M., Abudayyeh, Omar, Kim, Jong Wook, Cooper, Zachary A., Piris, Adriano, Frederick, Dennie T., Barzily-Rokni, Michal, Straussman, Ravid, Haq, Rizwan, Fisher, David E., Mesirov, Jill P., Hahn, William C., Flaherty, Keith T., Wargo, Jennifer A., Tamayo, Pablo, Garraway, Levi A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154497/
https://ncbi.nlm.nih.gov/pubmed/24771846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0424
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados